Medical technology jobs are booming in the US, but the workforce for those jobs is largely dominated by graduates.
As technology and surgical innovation become more prevalent, however, surgeons are becoming increasingly drawn to fields like technology, software development, and other engineering fields, says James R. Fenn, president and CEO of the American Association of Medical Colleges.
Fenn says there are more than 100,000 medical school graduates in the U.S. and more than 300,000 in their home countries, and he’s optimistic the industry will continue to grow as new skills are developed.
Forsberg, the co-founder of a company called BioCure that makes technology to treat blood clots, is one of the people who are excited about medical technology.
“I’m very bullish about the future of medical technology,” he says.
“We’re going to see a big change in the healthcare landscape in the next few years.”
Forsberges newest startup, BioCura, uses BioCURE technology to create a medical device that uses artificial blood vessels to treat diseases such as cystic fibrosis.
The technology is a breakthrough in stem cell therapies, which are a form of regenerative medicine.
“We’re able to take stem cells from the blood, and we’re able turn them into functional blood vessels,” says Fenn.
“And that enables us to treat disease in a patient, even if the disease is a genetic disease.”
BioCura was founded by Fenn and his wife, Laura, who have been involved in medical technology for years.
Laura Fenn worked at Apple before joining BioCuros, where she also worked as a senior scientist.
“Laura is really an innovator in all areas,” says Raffaello.
“She’s an industry leader in her field, and she’s really committed to the company and the company is committed to her.”
BioCare is one company Fenn founded after leaving Apple.
He says the company had been working with a team of researchers to develop a new blood-clotting test, but he says it was too expensive and took too long.
“It took me and Laura about four years to get it done,” says Forsberg.
“It took them about two and a half years.”
He says it’s about getting the technology to market.
BioCare uses the stem cells to create artificial blood-vascular devices.
It’s an approach that has some advantages over traditional stem cell therapy.
Instead of using a cell that has been made from a living cell, BioCare’s system uses a cell from a dead cell.
The process takes about two hours.
It is not as invasive as stem cell treatments, but there is still a need for more advanced stem cell technology.
Fellow BioCare co-founders Raffiella Rizzo and Danilo De Riva are now focused on a new technology that they call M-Cell.
The company says it can take about 10 hours to get a new M-cell into a patient.
M-Cell uses M-cells from the patient’s own cells.
It uses an advanced technology called pluripotent stem cells, which have the ability to grow into any type of cells in the body.
The cells are then grown and used in a dish, with a microscope to check their health.
“What’s exciting about this technology is that it can go from a single cell to a whole body,” says De Rivo.
“And that’s a huge benefit for patients.”
Foresberg is working on a company that will work with the U,S.
Food and Drug Administration to develop drugs that are able to treat a type of blood clot that was once a treatable disease.
The FDA has not approved the technology.
But the drug maker is not alone in trying to make stem cell medicine a reality.
In the U., two other companies have launched medical devices that use stem cells.
One of them is called BioVent, and the other is called Cell-X.
Cell-x uses stem cells taken from a patient’s skin cells to treat conditions like psoriasis.
The product is in the works for a U.K. market, and Foresberg says he hopes it can be available to the U-K.
Foresberges new company is called SBI Medical.
SBI specializes in medical devices.SBI Medical, which has been in the medical device business for more than a decade, has developed a device that can make blood clotting drugs, a major step forward in the field.
It says it has developed devices that can treat diseases like cancer and Alzheimer’s.
Sbi Medical’s CEO and co-chief scientist is Michael C. Tompkins, who was formerly a professor of biomedical engineering at Harvard Medical School.
He joined the company in 2011, and says he is very proud to have the same team at the helm.”SBI is a unique company, because we have the opportunity to create something that is so powerful,”